Microbiome Labs Unveils Enhanced Online Ordering Experience and Rebrand Shaped by Practitioner and Customer Feedback
Franklinton, North Carolina--(Newsfile Corp. - October 6, 2026) - Microbiome Labs™, a leader in spore-based probiotics and a division of Novonesis, announced the completion of a company-wide rebranding. Alongside this rebrand, the company launched a redesigned website and enhanced its online experience with capabilities that give practitioners a personalized way to provide education and recommend products directly to patients. These initiatives were unveiled to healthcare practitioners
2026-10-06 10:00 AM EDT | Microbiome Labs
Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen (OKG-0303) for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. To view the f
Biotechnology, Pharmaceuticals
2026-10-06 9:28 AM EDT | Okogen
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Grasonville, Maryland--(Newsfile Corp. - October 6, 2026) -
2026-10-06 8:30 AM EDT | OS Therapies
Izotropic Closes Non-Brokered Private Placement
British Columbia and Casablanca, Morocco--(Newsfile Corp. - October 6, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that further to its September 25th announcement it has com
2026-10-06 8:00 AM EDT | Izotropic Corporation
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bi
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-06 7:00 AM EDT | Phio Pharmaceuticals Corp.
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Biotechnology, Pharmaceuticals
2026-10-05 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking Association's (NIBA) 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida. Robert Bitterman, President and Chief Executive Offic
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-05 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking
Toronto, Ontario--(Newsfile Corp. - October 5, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology company transforming the storage, protection and management of temperature-sensitive medications, is pleased to announce that its VIVI Cap Smart™ platform now supports connectivity with Apple Health and Google Fit, advancing the Company's strategy to make injectable medication use visible within leading health and w
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-05 3:05 AM EDT | TempraMed Technologies Ltd.
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Grasonville, Maryland--(Newsfile Corp. - October 1, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer
2026-10-01 8:30 AM EDT | OS Therapies
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
Highlights PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service. Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutic
Biotechnology, Pharmaceuticals
2026-10-01 8:00 AM EDT | PharmaTher Holdings Ltd.
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California. World ADC San Diego is a leading global foru
Biotechnology, Pharmaceuticals, Health
2026-10-01 3:15 AM EDT | Defence Therapeutics Inc.
TempraMed Technologies Ltd. Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), is pleased to announce that, further to its September 23, 2026 and September 28, 2026 news releases, it has closed its non-brokered private placement (the "Offering") of unsecured convertible debentures of the Company (each, a "Convertible Debenture") and units (each, a "Unit"). The Company issued $600,000 of principal amount of C
Technology, Biotechnology, Pharmaceuticals, Health
2026-09-30 6:00 PM EDT | TempraMed Technologies Ltd.
Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
Calgary, Alberta--(Newsfile Corp. - September 29, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it has closed its non-brokered private placement (the "Offering"). Pursuant to the Offering, the Company issued an aggregate of 10,654,298 units (the "Units") at a price of $0.15 per Unit for aggregate gross p
2026-09-29 5:52 PM EDT | Marvel Biosciences Corp.
Appili Therapeutics Announces Transfer to NEX
Halifax, Nova Scotia--(Newsfile Corp. - September 29, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, announces that it has applied to voluntarily delist its Class A common shares (the "Common Shares") from the Toronto Stock Exchange (the "TSX") and transfer its listing to the NEX Board of the TSX Venture Exchange (the "NEX") as a resu
Biotechnology, Pharmaceuticals, industries.supplementary-medicine.name
2026-09-29 8:30 AM EDT | Appili Therapeutics Inc.
iSpecimen Supports Hospital Validation of New Chemistry Analyzer
Woburn, Massachusetts--(Newsfile Corp. - September 29, 2026) - iSpecimen, a provider of human biospecimens, is supporting a hospital laboratory in the validation of a new chemistry analyzer for clinical use. For the project, iSpecimen identified a healthcare system already using the same analyzer and is coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid (CSF), and urine specimens for use in the hospital's validation process. The specimens represent a broad
2026-09-29 8:05 AM EDT | iSpecimen Inc.
Ian Mortimer Receives the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award.
Technology, Biotechnology, Investment Banking, Health
2026-09-29 8:00 AM EDT | Bloom Burton & Co. Inc.
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Key Highlights Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-09-29 7:30 AM EDT | KALA Bio Inc.
BioHarvest Sciences Announces Share Repurchase Program
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in acc
Biotechnology, Pharmaceuticals, Health
2026-09-29 7:00 AM EDT | BioHarvest Sciences Inc.
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today reported additional clinical research results from its TELO-MRD program for multiple myeloma, including a comparison of blood-based TELO enumeration with matched bone marrow Adaptive
2026-09-29 3:30 AM EDT | Telo Genomics Corp.
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee. Sherry Aulin is a f
Biotechnology, Pharmaceuticals, Health
2026-09-29 3:15 AM EDT | Defence Therapeutics Inc.